Ohtuvayre FDA Approval History
FDA Approved: Yes (First approved June 26, 2024)
Brand name: Ohtuvayre
Generic name: ensifentrine
Dosage form: Inhalation Suspension
Company: Verona Pharma plc
Treatment for: COPD, Maintenance
Ohtuvayre (ensifentrine) is a selective dual inhibitor of the enzymes phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
- COPD refers to a group of diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis.
- Ensifentrine works in the treatment of COPD through combined bronchodilator and non-steroidal anti-inflammatory actions.
Development timeline for Ohtuvayre
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
